Astaxanthin, a powerful antioxidant derived from microalgae, yeast, and other natural sources, is widely used in dietary supplements, cosmetics, pharmaceuticals, and aquaculture. Its health benefits, such as reducing oxidative stress, improving skin health, and supporting cardiovascular health, have contributed to its growing popularity. The global astaxanthin market is experiencing significant growth due to increasing consumer awareness of wellness products and the rising demand for natural antioxidants.

Market Size and Growth

The global astaxanthin market is poised to grow at a compound annual growth rate (CAGR) of approximately 10.2% from 2022 to 2032, reaching an estimated value of US$ 2001.5 Mn by the end of the forecast period. This growth is driven by the escalating demand for natural health supplements, increased application in aquaculture, and the cosmetics industry’s emphasis on anti-aging products.

𝐆𝐞𝐭 𝐚 𝐆𝐥𝐢𝐦𝐩𝐬𝐞 𝐈𝐧𝐬𝐢𝐝𝐞: 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐤𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐚𝐧𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐬𝐚𝐦𝐩𝐥𝐞 – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16172

Market Segmentation

By Source Type:

Natural Astaxanthin (derived from microalgae, yeast, and krill)

Synthetic Astaxanthin

By Application:

Dietary Supplements

Pharmaceuticals

Cosmetics

Aquaculture and Animal Feed

By Industry Vertical:

Healthcare

Food and Beverage

Cosmetics and Personal Care

Aquaculture

By Region:

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

𝐆𝐞𝐭 𝐀 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: https://www.transparencymarketresearch.com/astaxanthin-market.html

Regional Analysis

North America: Leading the market due to high consumer awareness and the prevalence of health-conscious lifestyles.

Europe: Strong demand from the cosmetics and aquaculture industries.

Asia-Pacific: Rapid growth driven by increasing consumption of dietary supplements in emerging economies like India and China.

Latin America and Middle East & Africa: Gradual adoption driven by growing aquaculture activities.

Market Drivers and Challenges

Drivers:

Growing demand for natural and organic products in health supplements and cosmetics.

Increasing adoption of astaxanthin in aquaculture to enhance fish pigmentation and health.

Rising consumer preference for anti-aging and skin health products.

Challenges:

High production costs associated with natural astaxanthin.

Regulatory hurdles in certain regions regarding the approval of astaxanthin in food and supplements.

Market Trends

Increasing investment in R&D for efficient and sustainable production methods of natural astaxanthin.

Emergence of algae-based production as a sustainable and scalable method.

Growing use of astaxanthin in the development of functional foods and beverages.

Competitive Landscape

Key players in the astaxanthin market include BASF SE,

Cyanotech Corporation, Koninklijke DSM N.V., and Algatechnologies Ltd. These companies focus on strategic collaborations, product innovation, and capacity expansion to strengthen their market presence.

Future Outlook

The astaxanthin market is set to witness robust growth driven by advancements in microalgae cultivation technology, increased consumer inclination towards wellness, and expanding applications across diverse industries. Market players are likely to focus on sustainable practices and strategic alliances to capture the evolving consumer base.

Key Market Study Points

Analysis of natural versus synthetic astaxanthin trends.

Impact of regulatory frameworks on market dynamics.

Role of innovation in production technologies to reduce costs.

More Trending Reports by Transparency Market Research

Walnut Market- https://www.prnewswire.com/news-releases/walnut-market-size-is-projected-to-reach-usd-11-1-billion-at-a-4-3-cagr-by-2031-transparency-market-research-inc-302032434.html

Functional Flour Market – https://www.prnewswire.com/news-releases/functional-flour-market-worth-usd-147-3-billion-by-2031-at-7-6-cagr-report-by-transparency-market-research-inc-302024373.html

About Us:

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports

Contact Us:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

This release was published on openPR.

A short-term randomized study of active surveillance for prostate cancer showed that fish oil supplementation was associated with a reduction in a biomarker of disease progression.

During a year of follow-up, prostate biopsies showed about a 15% decrease in the Ki-67 index in patients who received fish oil capsules enriched for omega-3 fatty acids and low in omega-6. The index increased by 24% in men who did not receive the supplements. Secondary endpoints related to tumor characteristics did not change significantly between the randomized groups.

The findings support continued investigation of the fish oil intervention in phase III trials of prostate cancer, concluded William Aronson, MD, of the David Geffen School of Medicine at the University of California Los Angeles (UCLA), and colleagues in the Journal of Clinical Oncology.

“Patients in the trial were compliant with the intervention, which was well tolerated,” the authors stated. “Moreover, obtaining serial same-site prostate biopsy tissue is feasible for future biomarker intervention trials. On the basis of the underlying antiprostate cancer mechanisms of a high omega-3, low omega-6 diet with FO [fish oil] supplements, future trials are warranted evaluating this intervention in varying stages of prostate cancer.”

The trial met the primary endpoint (effect on Ki-67 index), but interpretation of the results should include recognition of certain limitations, according to the authors of an accompanying editorial. The magnitude of benefit was associated with wide confidence intervals (and a lower boundary of 2%), and the dietary intervention was not controlled.

“Instead, patients received monthly dietary counseling from a professional dietitian which resulted in a notable shift in habits, generally, in a positive direction,” noted Nazli Dizman, MD, and Andrea Necchi, MD, both of San Raffaele University in Milan. “This counseling resulted in a statistically significant reduction in participant’s total daily calorie intake and total fat and saturated fat consumption, with notable decreases in protein and carbohydrate intake.”

“Hence, the dietary changes prompted by the intervention in this study appear to have extended well beyond the intended shifts in the ratio of omega-6 and omega-3 fatty acid intervention, rendering it challenging to attribute the results of the study solely to the omega-6 and omega-3 fatty acid intervention,” they said.

The trial highlights the feasibility and complexity of dietary intervention trials, Dizman and Necchi continued.

“To better understand the mechanisms underlying the link between diet and outcomes and offer patients with prostate cancer evidence-based dietary guidance, continuous efforts through well-designed dietary intervention trials with robust translational correlatives will be essential,” they concluded.

Aronson’s group noted that patients with all stages of prostate cancer have demonstrated interest in dietary strategies and supplements that may help delay disease progression. To date, no specific clinical guidelines have provided recommendations.

Among previous studies of dietary interventions, the MEAL trial showed no effect of increased vegetable intake on prostate cancer progression during active surveillance. The CANARY study showed no impact of “healthy diet patterns” on upgrading of cancer during 7.8 years of follow-up.

Studies involving preclinical models have shown that lowering omega-6 and raising omega-3 fatty acids delayed prostate cancer progression, but epidemiologic studies have yielded mixed results, the authors noted. A cross-sectional study nested within a phase II study of men on active surveillance showed that higher omega-3 levels correlated with less clinical upgrading on prostate biopsies. A short-term pre-prostatectomy study showed that a low-fat diet supplemented with fish oil was associated with a decrease in the Ki-67 index cell-cycle progression score.

Following up the preclinical and clinical studies, Aronson and colleagues conducted the CAPFISH-3 trial, a 1-year prospective randomized study involving 100 men with grade group 1 or 2 prostate cancer on active surveillance at UCLA. Participants had a mean age of about 64; they were randomly assigned to no dietary intervention or to dietary counseling to reduce intake of dietary omega-6 and increase omega-3 intake, combined with daily fish oil supplements. The primary endpoint was change in Ki-67 index at 1 year based on prostate biopsies.

The results showed that the group assigned to the intervention had a reduction in biopsy-specific Ki-67 index from 1.34% at baseline to 1.14% at 1 year. During the same time the Ki-67 index increased in the control group, from 1.23% at baseline to 1.52% a year later. The results translated into a between-group difference of 31% (95% CI 2-52%, P=0.043).

Secondary endpoints did not differ between the groups, including upgrading or downgrading, maximal tumor length, or Decipher genomic classifier score. Testosterone and PSA levels also did not differ significantly between the groups. Serum triglycerides declined significantly in the intervention group versus the control group (P=0.016), but other lipid parameters did not differ between groups, nor did weight or BMI. With respect to cytokine activity, colony-stimulating factor-1 declined in the intervention versus control group (P=0.017).

Four patients in the intervention group withdrew because of adverse events related to fish oil, such as grade 2 flatulence, grade 2 diarrhea, and grade 1 loose stools.